The grant recipients of the Sedana Medical Research Foundation 2019 presented
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced the recipients of the Sedana Medical Research Foundation (SMRF) grant 2019. Three research projects will receive funding from SMRF 2019 covering the area of inhaled sedation in the intensive care field.
One of Sedana Medical´s missions is to improve patient outcomes through medical innovation. SMRF has been established to stimulate and support international research in the field of sedation of mechanically ventilated Intensive Care Unit (ICU) patients and to create a unique opportunity for the scientific community to increase knowledge of sedation therapies of critically ill patients.
Early 2019, SMRF had its first call for proposals. Many well-written and interesting applications were submitted. After independent scientific review and prioritization by Sedana Medical´s Clinical Development committee, three research groups were prioritized for funding in 2019:
Dr Giuseppe Foti, Associate professor and Director and dr Marco Giani, Department of Anesthesia and Intensive Care Department of Monza University Hospital, Italy.
Feasibility and safety of inhaled sedation in ECMO patients undergoing ultra-protective low frequency ventilation.
This study will investigate inhaled sedation delivered with the AnaConDa in (acute respiratory distress syndrome ARDS) patients undergoing veno-venous extracorporeal membrane oxygenation for respiratory failure with ultra-protective tidal volumes and low-frequency ventilation. Retrospective data indicate that this is possible, but positive findings may confirm that inhaled sedation, that appears to be lung-protective, may be used in patients normally considered too sick for uptake and elimination via the lungs.
Dr Gabriel Parzy, Dr Jean-Marie Forel, and Dr Laurent Papazian, Professor, Medical Intensive Care Unit service, Intensive Care Unit, Hôpital Nord, Marseille, France
Inhaled sedation effects on mean pulmonary artery pressure.
The main objective is to investigate potential reduction of pulmonary arterial pressure during inhaled sedation via the AnaConDa in moderate or severe ARDS patients. ARDS is associated with cardiopulmonary complications, including cor pulmonale and carries a high mortality. Reduced pulmonary pressures may potentially improve outcomes in these patients, however potential such effects of inhaled sedatives are not well studied previously.
Dr Martin Schläpfer, Associate professor, and Dr Beatrice Beck-Schimmer, Professor, Vice President Medicine, Institutes of Anesthesiology and Physiology, University and University Hospital Zurich, Switzerland.
Inhaled Sedation for Immunomodulation in Patients with Septic Shock – a pilot study.
This study will shed light on potential anti-inflammatory effects of inhaled sedation via the AnaConDa in septic shock. If this proves true, the implementation of this therapy may improve patient outcomes, such as mortality, in a critically ill patient group.
“We are happy for the great interest in moving research forward and improving patient care in this important medical field and wish all research groups success in their research”, states Peter Sackey, CMO Sedana Medical.
The next SMRF Call for proposals is planned for spring 2020.
For additional information, please contact:
Peter Sackey, CMO, Sedana Medical AB
Mobile: +46 70 771 03 64
Sedana Medical is listed on Nasdaq First North in Stockholm.
The company's Certified Adviser is Erik Penser Bank, +46 8 463 83 00, firstname.lastname@example.org.
Sedana Medical AB (publ) has developed and sells the medical device AnaConDa, for the administration of volatile anaesthetics to mechanically ventilated patients. A major clinical registration study is currently ongoing to obtain market approval in Europe for inhalation sedation in intensive care units with the pharmaceutical IsoConDa® (isoflurane).
Sedana Medical has direct sales in the Nordic countries, Germany, France, Great Britain and Spain as well as external distributors in the rest of Europe, Canada, Australia, Japan and South Korea. The company headquarters are based in Stockholm, Sweden with R&D operations in Ireland.